NHMRC Clinical Trials & Cohort Studies success
Congratulations to ViCBiostat Investigators on their recent success in the NHMRC Clinical Trials & Cohort Studies grant round. Of 30 total projects funded, we are delighted to see 11 of these involve one or more of our investigators on the team.
|
Grant |
Institution |
Funding |
ViCBiostat Investigator/s |
|
Uncovering the hidden impacts and costs of exposure to intimate partner violence in childhood: a 20-year cohort study |
Murdoch Children’s Research Institute |
$1,595,473 |
John Carlin |
|
Whole-of-population CRISPR point-of-care testing for congenital cytomegalovirus to prevent hearing and neurodevelopment disabilities through a public health approach |
Murdoch Children’s Research Institute |
$2,058,921 |
Margarita Moreno-Betancur |
|
Trans20: A longitudinal cohort study to improve outcomes for transgender children and adolescents |
Murdoch Children’s Research Institute |
$1,566,662 |
Monsurul Hoq |
|
Food allergy in the first 15 years of life: wave 5 of the HealthNuts longitudinal study |
Murdoch Children’s Research Institute |
$2,435,075 |
Margarita Moreno-Betancur Lyle Gurrin |
|
INTERCEPT (Investigating Novel Therapy to target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): a multi-arm, precision-based, recursive, platform trial |
Monash University |
$5,789,515 |
John Reynolds |
|
Reconceiving early detection of melanoma |
Monash University |
$3,217,920 |
Rory Wolfe |
|
Preventing infections in patients with blood cancer through evidence-based use of immunoglobulin or alternatives: The RATIONALISE trial |
Monash University |
$2,490,422 |
John Reynolds |
|
Clinical trial to determine the effects of statins on cognition: STAREE-Mind |
Monash University |
$2,795,200 |
Stephane Heritier |
|
Breathing Control as a treatment for Non-Epileptic Seizures |
University of Melbourne |
$1,740,187 |
Sabine Braat |
|
PRogrEssion of Diabetic ComplicaTions - PREDICT |
Baker Heart and Diabetes Institute |
$4,784,627 |
Agus Salim |
|
Intermittent preventive treatment in pregnancy with sulphadoxine-pyrimethamine plus dihydroartemisinin-piperaquine to reduce adverse pregnancy outcomes and prevent malaria in Papua New Guinea: a randomised controlled trial |
Menzies School of Health Research |
$2,938,453 |
Emily Karahalios |
|
|
|
|
|